-
Mashup Score: 0Racial and ethnic variation in body composition and prognosis of nonmetastatic breast cancer - 5 day(s) ago
Diagnostic imaging reveals differences in body composition by race and ethnicity and associations between adiposity and breast cancer–specific mortality that are masked using body mass index; specifi…
Categories: General Medicine NewsTweet
-
Mashup Score: 7Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas - 5 day(s) ago
Myxoid liposarcomas (MLS) are rare, malignant, mesenchymal tumors characterized by specific translocations t(12;16) and t(12;22) with limited additional driver mutations, most notably in PIK3CA and t…
Categories: General Medicine NewsTweet-
New & available #OpenAccess | Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas https://t.co/o8LOp8HGwo @OncoAlert https://t.co/hjUX7y4hbf
-
-
Mashup Score: 27Top advances of the year: The status of chimeric antigen receptor T cells in neuro‐oncology - 6 day(s) ago
Numerous major advances have been made in the past year regarding chimeric antigen receptor (CAR) T-cell therapy in neuro-oncology. Disialoganglioside GD2 CAR T cells, bivalent CAR T cells, and CARv3…
Categories: General Medicine NewsTweet-
There have been several key advances in the past year regarding CAR T-cell immunotherapy in neuro-oncology. This new commentary from @MichaelLimMD & @StanfordNsurg colleagues highlights some significant recent advances: https://t.co/1yexJ6nEb8 @OncoAlert @Ethan_Schonfeld https://t.co/3eBsdmTyS7
-
-
Mashup Score: 10Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials - 9 day(s) ago
Among patients with localized rhabdomyosarcoma (RMS), young patients and females had improved overall survival (OS). The OS of localized extremity RMS treated on D9803 was superior to ARST0531. Survi…
Categories: General Medicine NewsTweet-
New #OpenAccess paper from @sapna_pho et al analyzes data of patients with extremity rhabdomyosarcoma (RMS) treated on the @COGorg trials from 1998 to 2014. Outcomes for metastatic extremity RMS remain poor. https://t.co/UXEE7TYZ7Z @OncoAlert @AbbyRosenbergMD #ayacsm https://t.co/cMGQBL69Nl
-
-
Mashup Score: 14
Click on the article title to read more.
Categories: General Medicine NewsTweet-
According to a phase 3 study in @NEJM, cabozantinib improves progression-free survival in advanced neuroendocrine tumors. Cabozantinib is now FDA-approved for previously treated patients 💊 🔍The latest #CancerScope offers analysis: https://t.co/dor3e2mVWN @OncoAlert https://t.co/gnm1DqhYvo
-
-
Mashup Score: 13
Click on the article title to read more.
Categories: General Medicine NewsTweet-
Available in #CancerScope! A 7-year study in The Lancet Oncology shows nivolumab + ipilimumab helps people w/ melanoma brain metastases live longer 🧠 CANCER Section Editor @jasonlukemd explains why this combination is now the go-to treatment https://t.co/4o6LQ3ybDB @OncoAlert https://t.co/xxhOA0f2T6
-
-
Mashup Score: 10Deep learning model for predicting immunotherapy response in patients with advanced NSCLC - 10 day(s) ago
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, study findings demonstrate a strong and independent dee…
Categories: General Medicine NewsTweet-
🔬 Can AI read H&E slides to predict immunotherapy response in advanced NSCLC? Find out in a new JAMA Oncology study—plus insights from CANCER Section Editor Dr. Daniel Morgensztern—as featured in the latest #CancerScope: https://t.co/kzzqTmvzsK @OncoAlert #LCSM https://t.co/giXsHuCh4A
-
-
Mashup Score: 15Top advances of the year: Neoadjuvant immunotherapy in melanoma - 11 day(s) ago
Overall, much progress was made in 2024 in the realm of neoadjuvant immunotherapy including the firm establishment of neoadjuvant immunotherapy as superior to only adjuvant immunotherapy for patients…
Categories: General Medicine News, Onc News and JournalsTweet-
Coming up at the #ASCO25 Poster Session: Dr. Michael Postow shares new research on immune cell imaging to predict immunotherapy response in advanced cancers. See his latest work with @MonicaChenMD on immunotherapy timing in stage III melanoma: https://t.co/w62CQt6Cyd @OncoAlert https://t.co/3qONQ2u3wZ
-
-
Mashup Score: 29Annual Report to the Nation on the Status of Cancer, featuring state‐level statistics after the onset of the COVID‐19 pandemic - 12 day(s) ago
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annu…
Categories: General Medicine NewsTweet-
The latest #CancerAnnualReport is here & reveals that cancer deaths in both men & women declined for more than 20 years, even during the first 2 years of the #COVID19 pandemic. Read the key trends: https://t.co/cxVzMyqiAS @OncoAlert @AhJemal @ACSNews @theNCI @CDCgov @NAACCR https://t.co/mOtiR23R5c
-
-
Mashup Score: 28Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer - 12 day(s) ago
Early clearance of circulating tumor DNA in patients who had advanced non-small cell cancer with a KRASp.G12C mutation predicted benefit from sotorasib therapy. Conversely, a dynamic increase in the …
Categories: General Medicine NewsTweet-
New #OpenAccess research from @UmbertoMalapel1 et al in time for the conclusion of #ASCO25 | Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer https://t.co/7D8Mw6RpF8 @OncoAlert #LCSM https://t.co/Gs9MNv4HoM
-
New routine imaging findings from Ijeamaka A. Fumagalli MPH of @KPDOR et al highlight opportunities for tailored lifestyle interventions to improve survivorship and mitigate disparities. https://t.co/anQVPD26vv @OncoAlert @ewarner_12 https://t.co/YwfWpDQNDd